Home › Triple-Negative Breast Cancer › Pennsylvania › York
Triple-Negative Breast Cancer clinical trials in York, PA
4 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around York (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- WellSpan York Cancer Center, York
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RecruitingPhase 3
- Cancer Care Associates Of York ( Site 9517), York
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- Cancer Care Associates of York, York
CtDNA Based MRD Testing for NAC Monitoring in TNBC
RecruitingObservational study
- Cancer Care Associates of York, York
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in York
- Non-Small Cell Lung Cancer15 studies
- Cancer (all types)8 studies
- Breast Cancer8 studies
- Lung Cancer8 studies
- Head and Neck Squamous Cell Carcinoma7 studies
- Ovarian Cancer6 studies
- Prostate Cancer5 studies
- Coronary Artery Disease5 studies
- Esophageal Cancer4 studies
- Colorectal Cancer4 studies
- Endometrial Cancer4 studies
- Colon Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.